Vorasidenib - Pharmacological Aspects Overview

Overview:

Vorasidenib tablets contain the active ingredient Vorasidenib, which works by inhibiting enzymes called IDH1 (intradialytic hypotension 1) and IDH2. The Vorasidenib in the tablets is combined with other chemicals to form a specific crystalline structure. The chemical formula of this structure is quite complex, and its molecular weight is 519.8 g/mol (grams per mole). Vorasidenib appears as a white to off-white solid that does not dissolve well in water at a pH between 1.2 and 6.8. Vorasidenib tablets come in two strengths: 10 mg (milligrams) and 40 mg, which refer to the amount of Vorasidenib in each tablet. The tablets also contain several inactive ingredients that help with the tablet's structure and absorption, including croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The coating on the tablets is made of hypromellose, lactose, macrogol, and titanium dioxide. The black ink printed on the tablets contains black iron oxide, hypromellose, and propylene glycol.

Available Doses and Dosage Forms:

The tablets come in two strengths:

• 10 mg (Milligrams): Small, round, white, or off-white tablets with number 10 printed in black on one side. Each tablet contains 10 mg of the active ingredient Vorasidenib.

• 40 mg (Milligrams): Large, oblong, white, or off-white tablets with number 40 printed in black on one side. Each tablet contains 40 mg of Vorasidenib.

For Patients:

What Is Grade 2 IDH-Mutant Glioma?

IDH-mutant grade 2 gliomas are harmful to brain tumors and can lead to serious health issues and early death. Vorasidenib is a pill that can enter the brain and target these specific tumor enzymes, showing early promise in treating these tumors.

How Does Vorasidenib Work?

A study examining how Vorasidenib works was found to significantly lower the levels of a harmful substance linked to IDH mutations and correct the genetic changes caused by the mutant IDH1 enzyme.

What Are the Things to Inform the Doctor Before Taking the Vorasidenib?

• Let the doctor know about the person’s liver problems or kidney issues or if the person is on dialysis.

• Inform the doctor if using tobacco for smoking.

• Vorasidenib can harm an unborn baby.

• The doctor will do a pregnancy test before prescribing Vorasidenib. Use reliable non-hormonal birth control while on Vorasidenib and for three months after finishing the treatment, as hormonal birth control might not work as well. If trying to become pregnant or being pregnant, tell the doctor right away.

• Use effective birth control during the treatment with Vorasidenib and for three months after stopping the drug. If the partner becomes pregnant or thinks she might be pregnant during the treatment, let the doctor know immediately.

• We do not know if Vorasidenib passes into breast milk, so do not breastfeed while on Vorasidenib and for two months after the last dose.

• Tell the doctor about all the medications taken, including over-the-counter drugs, vitamins, and herbal supplements. Vorasidenib might change how other medicines work, and other medicines might affect how Vorasidenib works.

• Keep a list of all the medicines to share with the doctor or pharmacist whenever starting a new medication.

How Is Vorasidenib Administered?

• Before beginning treatment with Vorasidenib, doctors will check the blood and liver function.

• Vorasidenib is for people with specific brain tumors (grade 2 astrocytoma or oligodendroglioma) that have certain genetic mutations (IDH1 or IDH2). However, there is no FDA-approved test yet to detect these mutations.

• Adults should take 40 mg of Vorasidenib once a day. Any decision regarding drug modification should be taken only if the disease worsens or side effects become too severe.

• Children 12 years and older, weighing 40 kg (kilograms) (about 88 lbs (pound)) or more, should take 40 mg once a day. If the child weighs less than 40 kg, they should take 20 mg once a day.

• Swallow the Vorasidenib tablets whole with water, either with or without food. Do not split, crush, or chew the tablets.

What Are the Side Effects of Vorasidenib?

• Liver problems (Hepatotoxicity).

• Risk to Unborn Babies (embryo-fetal toxicity).

• Fatigue.

• Headache.

• COVID-19.

• Muscle and joint pain.

• Diarrhea.

• Nausea.

• Seizures.

• Increased liver enzymes (ALT (alanine transaminase) and AST (aspartate aminotransferase)).

• Increased GGT (gamma-glutamyl transpeptidase) (another liver enzyme).

• Decreased neutrophils (a type of white blood cell).

• Increased liver enzymes (ALT and AST).

• Increased GGT (another liver enzyme).

• Decreased neutrophils (a type of white blood cell).

• Other changes included increased creatinine, glucose, and decreased calcium.

Missed Dose: Take Vorasidenib at the same time every day. If a dose is missed, it should be taken immediately within six hours as soon as the person remembers. If more than six hours have passed, skip the missed dose and take the next one at the regular time.

Storage: Keep Vorasidenib tablets at room temperature between 68 and 77 °F (degrees Fahrenheit) (20 to 25°C (degrees Celsius)). It is okay if the temperature goes a bit higher or lower, but not outside the range of 59°F to 86°F (15°C to 30°C).

For Doctors:

Indication:

• Vorasidenib is a medication prescribed for adults and children aged 12 and older who have Grade 2 astrocytoma or oligodendroglioma, which are specific types of brain tumors.

• It is meant for patients with tumors with genetic mutations (IDH1 or IDH2).

• This treatment is used after the tumor has been surgically removed or sampled, whether partially or completely.

Dosing Considerations:

1. For Adults: Take 40 mg of Vorasidenib once daily until the disease worsens or side effects become too severe.

2. For Children 12 Years and Older:

   • If the child weighs 40 kg (88 lbs) or more, then they should take 40 mg once a day.

   • If the child weighs less than 88 lbs, then they should take 20 mg once a day.

3. Liver Issues: Depending on the severity of liver problems, the doctor may either continue the current dose, temporarily stop the medication, reduce the dose, or permanently stop the treatment.

4. Other Severe Side Effects: If a person experiences severe side effects, the doctor may pause the treatment and later reduce the dose. If the side effects are severe or it returns after adjusting the dose, the treatment may be permanently discontinued.

What Are the Pharmacological Aspects of Vorasidenib?

• Pharmacodynamics: Vorasidenib helps lower levels of a harmful substance called 2-HG in tumors of patients with IDH1 or IDH2 mutated glioma. In studies, tumors of patients who took Vorasidenib had a significant reduction in 2-HG levels between 64 percent and 93 percent compared to those who did not receive the treatment. It was seen that this reduction was in patients who had been administered doses that were relatively close to the recommended dosages. The precise balance between the concentration of Vorasidenib in the bloodstream, its toxicity, and its effectiveness, ranging over time, has not been fully established. If taken as directed, that is, one hour before a meal, Vorasidenib is unlikely to prolong the QTc interval, which is a measure of heartbeat rhythm. Thus, the drug’s impact on the cardiovascular system is unclear at increased concentrations, for example, when taken with food or with other products.

• Mechanism of Action: Vorasidenib can be described as a small molecule that selectively binds and eventually suppresses IDH1 and IDH2 enzymes. These enzymes can exist in both normal (wild type) and mutated forms. In lab tests, Vorasidenib was effective against both the normal and mutated versions of these enzymes, including specific mutations like R132H. In studies using cells and animal models with tumors that have IDH1 or IDH2 mutations, Vorasidenib reduced the production of a harmful substance called 2-hydroxyglutarate (2-HG) and helped the cells start returning to their normal functions.

• Pharmacokinetics: When taken in doses ranging from 10 to 200 mg, the levels of Vorasidenib in the blood increase roughly in proportion to the dose. At the recommended dose, it reaches steady levels in the body after about 28 days, and the concentration in the blood (Cmax) averages 133 ng/mL (nanogram per milliliter). The drug's overall exposure (AUC) is 1,988 h•ng/mL, and it tends to accumulate in the body over time.

  • Absorption: After taking the medication, it takes about two hours (ranging from 0.5 to four hours) to reach peak concentration in the blood. The oral bioavailability of the drug is estimated at 34 percent, which implies that just a third of the drug is assimilated into the bloodstream.

  • Food Effect: A high-fat, high-calorie meal increased the drug concentration by three times. As for the levels of harm, there was one time for the peak level and 1. 4 times overall. A low-fat, less-calorie meal also helps in increasing concentration but not to the same extent as a high-protein, low-fat, and low-calorie.

  • Distribution: Studies reveal that Vorasidenib has a large volume of distribution of about 3,930 fluid ounces, implying it moves freely in the body. It has a high affinity for proteins in the blood (97 percent) and has easy access to the brain; the proportion of concentration of the drug in the brain and blood is 1: 1.6.

  • Elimination: It carries a half-life of about 10 days which implies that it remains in the body for quite some time. It is cleared from the body at a rate of 14 fluid ounces per hour.

  • Metabolism and Excretion: Vorasidenib also undergoes metabolism, and it is CYP1A2 that is said to be predominantly involved in the metabolism of Vorasidenib, with other enzymes such as CYP2B6 and CYP2C8 also playing a small role. Some 85 percent of the drug is excreted in feces — 56 percent of it in the unchanged form, and four. The rest 5 percent is excreted in the urine.

Clinical Studies: The benefits of Vorasidenib were determined in a randomized control trial, which was named the INDIGO trial. This was a multicentral study and included 331 patients with a type of glioma with defined genomic alterations. The subjects were divided into two groups, and the former took Vorasidenib while the latter received a placebo, which is a drug with no active ingredients at all, every single day. It was a double-blind technique in which patients and doctors were also unaware of the fact that which group was taking real medicine and which one was taking the placebo medicine. Subjects were followed until the patient’s disease progressed or they developed intolerable side effects. Tumor evaluations were performed every three months on average.

Regarding patients’ demographics in the study, 168 patients received Vorasidenib while 163 patients received the placebo. About one-half of the patients were male and the average age was thirty-five years, most of them white males. The majority of patients had prior surgery either as one or more operations before enrolling in the study. The mutation that was identified in the samples analyzed most frequently was R132H.

The primary outcome assessment was taken through progression-free survival (PFS), which depicts the period that patients spent without worsening their disease. Therefore, the study revealed that overall survival with the existence of progression-free survival was significantly higher among the patients who were under Vorasidenib as opposed to those who took the placebo. Specifically, Vorasidenib lowered the hazard ratio for the disease-related outcomes by about 61 percent as compared to the placebo.

The final was the time interval between the time patients were last treated and the time they required new treatment. Findings on the efficacy and safety of drugs and other interventions showed an overall improvement of 13.7 percent after five months among the group that was given the active drug, while 9.2 percent of the placebo group had similar improvement. Reduction of depressive symptoms by 50 percent among the active drug group after eight months, while the symptoms among the placebo group also reduced by four percent after the same period. This means that patients on Vorasidenib had more time to receive no further cancer treatment after the trial than patients on placebo.

Warnings and Precautions:

• Liver Problems (Hepatotoxicity): Pulmonary hypertension might also be worsened by Vorasidenib, and the patients’ livers might become inflamed and be at risk of liver failure, liver cell death, or autoimmune hepatitis. Through treatment, doctors will check the patient’s liver frequently, and if the condition worsens, then the medication may be altered or discontinued.

• Risk to Unborn Babies (Embryo-Fetal Toxicity): Vorasidenib affects the developing baby throughout pregnancy if the pregnant woman uses the medication. It was found that this substance is toxic to the embryos when administered to pregnant rats and rabbits at a dosage many times higher than that used by humans. Any woman who is pregnant or may become pregnant must be advised of the dangers to the unborn child. Females of childbearing potential should avoid becoming pregnant while receiving Vorasidenib and for three months after the last administration of Vorasidenib as Vosa- denib may reduce the efficacy of hormonal contraceptives. Also, the male partners of the female clients capable of child-bearing should ensure that they exercise adequate contraception while on the regime and for three months after completing the treatment regime.

What Are the Drug Interactions of Vorasidenib?

• Impact of Strong and Moderate CYP1A2 Inhibitors: Taking Vorasidenib along with strong or moderate CYP1A2 inhibitors (can increase the amount of Vorasidenib in the blood, raising the chance of side effects. Avoid using these inhibitors with Vorasidenib. If there is a need to take a moderate inhibitor, watch closely for side effects and adjust the dose of Vorasidenib as needed.

• Impact of Moderate CYP1A2 Inducers: Taking Vorasidenib with moderate CYP1A2 inducers (including smoking tobacco, which speeds up how the body processes Vorasidenib) can lower the amount of Vorasidenib in the blood, making it less effective against tumors. Avoid using these inducers and stop smoking while taking Vorasidenib.

• Impact on Certain CYP3A Substrates: Vorasidenib can lower the levels of drugs that rely on the CYP3A enzyme to work properly, which might make those drugs less effective. Avoid taking Vorasidenib with these types of drugs.

• Impact on Hormonal Contraceptives: Vorasidenib can lower the levels of hormonal contraceptives in the body, possibly leading to contraceptive failure and unexpected bleeding. If one has to take both, use non-hormonal birth control methods.

Specific Considerations:

• Pregnancy: There is a risk of Vorasidenib affecting an unborn baby when the medicine is used during pregnancy. In pregnant women, there is no particular data, but based on the studies conducted among animals and their fetuses, it was established that the drug can lead to body disorders in the fetus.

• Lactation: It is not yet known if Vorasidenib crosses the breast milk barrier, in addition to the effects that may be observed on the breastfed child. Women are warned against breastfeeding during the treatment and for one and a half months after using the medicine.

• Females and Males of Reproductive Potential: Women who could become pregnant should confirm they are not pregnant before starting Vorasidenib. Women should use non-hormonal birth control during treatment and for three months after the last dose, as Vorasidenib might make hormonal contraceptives less effective. For men who have a partner who is planning for pregnancy or pregnant, they should also follow birth control throughout the treatment and three months later. Vorasidenib may limit the ability to have children, and the future impact of Vorasidenib on childbearing men and women based on research on animals is questionable.

• Pediatric Use: Vorasidenib is used in children aged 12 years old and above with certain types of brain tumor, namely, grade 2 astrocytoma or oligodendroglioma with IDH1- or IDH2-mutation. It is found that the drug is effective in both adults and children. However, it has not been investigated or recommended for use for children under the age of twelve.

• Geriatric Use: Few patients of more than sixty-five years of age were involved in the studies, so there is no clear picture of whether seniors have a different reaction to Vorasidenib than younger people.

• Renal Impairment: In patients with mild to moderate impaired renal function, no dose adjustment is necessary. Nonetheless, Vorasidenib has not been evaluated in certain conditions, such as severe renal impairment or patients on dialysis. Regarding these patients, precautions such as the close observation of side effects as well as the modification of the dose should be taken.

• Hepatic Impairment: It is not necessary to adjust the dose in patients with mild and moderate impairment of liver function. Yet Vorasidenib has not been investigated in patients with severe hepatic impairment, so these patients, should be closely monitored for side effects and may require dose modifications.